FIELD: biotechnology.
SUBSTANCE: described herein describe ranpirnase and amphinase, compositions containing ranpirnase and/or amphinase, as well as methods and applications for treating viral conjunctivitis, epidemic keratoconjunctivitis and/or pharyngoconjunctival fever, reducing or suppressing virus or titre level of virus, reducing or suppressing viral replication, reducing or suppressing protein synthesis, reducing or suppressing tRNA level, reducing or suppressing the level of inflammatory inducing molecule and/or prostaglandin inducing inflammation, stimulating or improving peroxisome proliferator-activated receptor pathway signal (PPAR), facilitating establishment of change of phenotype M1 in M2, modulation of Th1- and Th2-cytokines and/or reduction or suppression of signal NFκB-pathway using ranpirnase, amphinase or composition containing ranpirnase and/or amphinase.
EFFECT: what is offered is treatment of viral conjunctivitis with application of ranpirnase and/or amphinase.
18 cl, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL PREPARATIONS FOR TREATING VIRAL INFECTIONS OF EYE | 2016 |
|
RU2739392C2 |
| METHODS AND PRODUCTS FOR EXPRESSION OF PROTEINS IN CELLS | 2013 |
|
RU2711249C2 |
| ANTI-PD-1 ANTIBODIES | 2015 |
|
RU2711141C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY USING NON-DEPLETION B-CELL INHIBITORS | 2020 |
|
RU2821892C2 |
| VACCINE | 2012 |
|
RU2640258C2 |
| CANCER TREATMENT USING ANTI-NKG2A AGENTS | 2015 |
|
RU2721271C2 |
| TREATMENT OF INFLAMMATION, AUTOIMMUNE, AND NEURODEGENERATIVE DISORDERS WITH IMMUNOSUPPRESSIVE TAT DERIVATIVE POLYPEPTIDES | 2013 |
|
RU2653754C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUS B AND WAYS FOR APPLICATION THEREOF | 2015 |
|
RU2711932C2 |
